Reynolds Tobacco Company Wins U.S. Supreme Court Support to Challenge FDA Ruling Locally

Jun.23.2025
Reynolds Tobacco Company Wins U.S. Supreme Court Support to Challenge FDA Ruling Locally
On June 20, the U.S. Supreme Court ruled 7-2 in favor of e-cigarette companies, making it easier for them to sue over FDA decisions blocking product market entry. The case, filed by RJ Reynolds, challenges FDA’s denial of the Vuse Alto e-cigarette. The ruling could shift the balance between the industry and regulators.

Key Points:

 

·Court ruling: In a 7-2 decision, the Supreme Court supports e-cigarette companies, loosening litigation restrictions and allowing more businesses to challenge FDA bans. 

 

·Case background: Reynolds e-cigarette company (RJ Reynolds) filed a lawsuit against the FDA for refusing to authorize its Vuse Alto e-cigarette. 

 

·The company partnered with retailers in Texas, a conservative majority state, to file the lawsuit in the Fifth Circuit Court of Appeals. 

 

·Legal impact: Retailers and distributors affected by FDA decisions can now file lawsuits in local courts, not just manufacturers. 

 

·This may increase e-cigarette companies' chances of choosing favorable courts. 

 

·Judicial division: Majority opinion (Justice Barrett): Believes the law allows affected businesses (like retailers) to file lawsuits. 

 

·Dissenting opinion (Justices Jackson and Sotomayor): Warns that the ruling could undermine regulatory consistency and promote evasion behavior. 

 

·Industry and regulatory conflict: FDA has recently strengthened control over flavored e-cigarettes, but the industry continues to push back through legal means. 

 

·This ruling may weaken FDA's regulatory efforts and impact the future landscape of the e-cigarette market.

 

·The ruling marks a key victory for the e-cigarette industry in its fight against federal regulations, potentially leading to more similar lawsuits and further affecting e-cigarette policies in the US.

 


 

According to a report from the Associated Press on June 20th, the Supreme Court of the United States voted 7-2 in favor of Reynolds Vapor Co., a subsidiary of Reynolds Tobacco, allowing them to challenge the FDA's decision to refuse their e-cigarette marketing application in the Fifth Circuit Court of Appeals.

 

At the time of this ruling, major e-cigarette companies are opposing the federal government's years-long crackdown on e-cigarettes. It is expected that the ruling will give e-cigarette companies more autonomy to decide which judges will preside over lawsuits against e-cigarette entities.

 

In a ruling in April, judges reversed their stance on e-cigarettes, supporting the FDA's decision to maintain a comprehensive ban on most flavored e-cigarettes following a surge in youth vaping.

 

The current case is brought by the Reynolds e-cigarette company, which had already sold a range of popular berry and mint-flavored e-cigarette products before the FDA began regulating the market in accordance with the Tobacco Control Act in 2016.

 

The FDA has rejected approval of the company's Vuse Alto product. Supreme Court Justice Amy Coney Barrett wrote in the majority opinion that this decision "rings the death knell for a significant portion of the e-cigarette market.

 

The company is headquartered in North Carolina, where it is typically only able to challenge the FDA in local courts or in the FDA's headquarters in Washington D.C. However, the company has teamed up with a Texas-based business that sells its products to file a lawsuit locally. The conservative U.S. Fifth Circuit Court of Appeals has allowed the lawsuit to proceed, ruling that any business that suffers harm to its operations due to an FDA decision can file a lawsuit.

 

The FDA has filed an appeal to the Supreme Court, alleging that the e-cigarette company Reynolds is attempting to find a favorable court for its arguments.

 

However, judges found that the law does allow other businesses, such as e-cigarette retailers, affected by FDA decisions to file lawsuits in their state.

 

Supreme Court Justices Ketanji Brown Jackson and Sonia Sotomayor, who hold differing opinions, both agree that they will stand by the institution.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Japan Tobacco Inc. (JT) confirmed on November 9, 2026, that all seven of its Russian entities had been placed under temporary administration after a second presidential decree added three companies to the four designated a day earlier. The additional entities are associated with importing, management, holdings and the former supply of Ploom heated-tobacco devices. JT disclosed approximately ¥1.5 trillion in Russian business-related assets as of September 30, including ¥360 billion in cash and deposits, and approximately ¥200 billion in liabilities. Under its revised FY2026 forecast, Russia accounts for about 25% of adjusted operating profit. JT said operations in Russia were continuing, while the financial impact remained under assessment.
company
Nov.09
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14